The quarter mostly confirms what investors already knew. The $125 million Regeneron collaboration was announced on May 18, 2026, and the $770.5 million IPO closed on June 11, 2026, so the partnership and balance-sheet transformation are not new surprises.
The financial picture is substantially stronger, but the operating result is still a normal clinical-biotech burn story. Cash, cash equivalents and marketable securities reached $1.1 billion from $27.7 million at year-end, which management says funds operations into 2030; quarterly R&D rose to $39.4 million and G&A to $11.7 million, while net loss widened to $52.5 million from $34.8 million. (Balance Sheets; Statements of Operations)
| Metric | Q2 2026 | Q2 2025 / prior comparison |
|---|---|---|
| Collaboration revenue | $0.15M (Statements of Operations) | $0 (Statements of Operations) |
| R&D expense | $39.4M (Statements of Operations) | $30.1M (Statements of Operations) |
| G&A expense | $11.7M (Statements of Operations) | $6.4M (Statements of Operations) |
| Net loss | $52.5M (Statements of Operations) | $34.8M (Statements of Operations) |
| Cash, equivalents and marketable securities | $1.1B (Balance Sheets) | $27.7M at Dec. 31, 2025 (Balance Sheets) |
There is no new clinical readout to re-rate the lead program. The filing repeats the existing development path: more mature desmoid data in Q4 2026, FDA discussions in Q4 2026, and a planned Phase 3 start in the first half of 2027. The key near-term event is the February data-cut presentation at ESMO from October 23–27, 2026. (Recent Business Highlights — Desmoid tumors)
The Regeneron deal expands optionality, not near-term value visibility. The $50 million upfront payment and $75 million equity investment provide validation and funding, while the potential $2.2 billion in milestones and tiered royalties remain contingent on successful development and commercialization. (Expanded the Application of the Helicon Platform)
Net read: financially de-risked, clinically unchanged. The balance sheet is a meaningful improvement and operating expenses are tracking the company’s broader pipeline buildout, but the filing supplies no fresh efficacy result, regulatory win, or accelerated timeline beyond what was already expected. That makes the quarter broadly in line rather than a fundamental beat or miss.
Read the original 8-K on SEC EDGAR ↗